Avoidable drug-gene conflicts and polypharmacy interactions in patients participating in a personalized medicine...

Area of Science:

• Pharmacogenetics
• Clinical Pharmacology
• Genomic Medicine

Background:

• Drug-gene interactions (DGIs) and drug-drug interactions (DDIs) pose significant risks in patient care.
• Identifying these interactions is crucial for optimizing medication regimens and preventing adverse events.

Purpose of the Study:

• To evaluate the efficacy of the PRIMER pharmacogenetic service in identifying actionable DGIs and DDIs.
• To assess the prevalence of these interactions in a patient population across various conditions.

Main Methods:

• PRIMER utilizes specific patient selection criteria and a comprehensive gene panel.
• Actionable guidance for managing identified DGIs and DDIs is provided.
• The service incorporates evidence-based interpretation and review of potential DDIs.

Main Results:

• PRIMER identified significant DGIs in 73% of patients, with 43% experiencing multiple DGIs.
• Drug-drug interactions (DDIs) were detected in 87% of patients.
• Common actionable DGIs involved opioid, psychotropic, and cardiovascular medications.

Conclusions:

• The integrated approach of PRIMER, combining patient selection, a multigene panel, and DDI review, maximizes patient benefit.
• The service effectively alerts physicians to necessary medication regimen adjustments.
• This pharmacogenetic service enhances patient safety and therapeutic outcomes.